Soligenix appoints Rasappa Arumugham as vice president of biopharma development

23 September 2014

Inflammation, oncology and biodefense biopharma company Soligenix has announced the appointment of Rasappa Arumugham as vice president of biopharmaceutical development.

Dr Arumugham has a background of more than 25 years of biopharma research and development in formulation research, analytical method development, quality control and manufacturing. He has been involved in the development, scale-up and technology transfer to support the commercialization of vaccines and biologics such as Prevnar, Tetramune and Meningitec Conjugate.

Most recently he has been head of microbial vaccines analytics in the manufacturing division of pharma giant Merck & Co (NYSE: MRK), and before this held positions at Praxis Biologics, Lederle, Wyeth and Pfizer, where he served as senior director of analytical biotherapeutics research and development for biologics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK